Bone fragility in men - where are we?
- E. Seeman,
- G. Bianchi,
- S. Khosla,
- J. A. Kanis,
- E. Orwoll
- … show all 5 hide
Rent the article at a discount
Rent now* Final gross prices may vary according to local VAT.
Get AccessAbstract
Introduction
This is a summary of several aspects of the epidemiology, pathogenesis and treatment arising directly and indirectly from the proceedings of the Third International Osteoporosis in Men meeting held in Genoa in May 2005. Advances in the study of bone fragility in men have taken place, but many challenges remain.
Observations
Although the epidemiology of hip fractures is well documented, the epidemiology of other non-vertebral fractures is less well defined even though these fractures contribute substantially to the global burden of fractures in men. The epidemiology of vertebral fragility fractures is derived mostly from cross sectional data. The comparable prevalence of vertebral fractures in men and women is likely to be misleading because of traumatic vertebral fractures that arise in young men. Prospective studies are needed to define the proportion of these fractures that are traumatic. After the age of 50 years, the incidence of vertebral fractures in men is about one third to one half of that in women. As in women, most vertebral and non-vertebral fragility fractures occur in persons without osteoporosis. Identifying these individuals is an unmet challenge. The absolute risk for fractures appears no different by sex in men and women of the same age and bone mineral density (BMD) so that the diagnostic threshold for osteoporosis in women can be used in men. Fracture risk varies around the world and is unlikely to be explained solely by variations in BMD, though there are few data comparing men and women of different races. Both the notion that men lose less bone than women from the endosteal envelope and that they gain more on the periosteal envelope during advancing age needs reassessment as recent evidence challenges these observations. Sex differences in the net gain and loss from these surfaces are likely to be site specific, and research is needed to specify this heterogeneity and the reasons for it. The independent and co-dependent effects of sex hormones and the growth hormone/insulin like growth factor 1 axis on periosteal and endosteal modeling and remodeling during growth as well as ageing are poorly defined. The anti-fracture efficacy and safety of androgens and other agents remain incompletely investigated in men.
Conclusion
A great deal of research is needed to advance our understanding of bone fragility in men.
- Cooper, C, Dennison, EM, Leufkens, HGM, Bishop, N, Staa, TP (2004) Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 19: pp. 1976-1981 CrossRef
- Johnell, O, Kanis, JA, Jonsson, B, Oden, A, Johansson, H, Laet, C (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16: pp. 222-228 CrossRef
- Jiang, HX, Majumdar, SR, Dick, DA, Moreau, M, Raso, J, Otto, DD, Johnston, DWC (2005) Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 20: pp. 494-500 CrossRef
- Kanis, JA, Oden, A, Johnell, O, Laet, C, Jonsson, B, Oglesby, AK (2003) The components of excess mortality after hip fracture. Bone 32: pp. 468-473 CrossRef
- Khosla, S, Lufkin, EG, Hodgson, SF, Fitzpatrick, LA, Melton, LJ (1994) Epidemiology and clinical-features of osteoporosis in young individuals. Bone 15: pp. 551-555 CrossRef
- Orwoll, ES, Klein, RF (1995) Osteoporosis in men. Endocr Rev 16: pp. 87-116 CrossRef
- Schuit, SCE, Klift, M, Weel, AEAM, Laet, CEDH, Burger, H, Seeman, E, Hofman, A, Uitterlinden, AG, Leeuwen, JPTM, Pols, HAP (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34: pp. 195-202 CrossRef
- Szulc, P, Munoz, F, Duboeuf, F, Marchand, F, Delmas, PD (2005) Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporos Int 16: pp. 1184-1192 CrossRef
- Sornay-Rendu, E, Munoz, F, Garnero, P, Duboeuf, F, Pierre, D, Delmas, PDD (2005) The identification of osteopenic women at high risk of fracture : the OFELY Study. J Bone Miner Res 20: pp. 1929-1943 CrossRef
- Kanis, JA, Johnell, O, Oden, A (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12: pp. 989-995 CrossRef
- Kanis, JA, Oden, A, Johnell, O (2001) The burden of osteoporotic fractures: a method of setting intervention thresholds. Osteoporos Int 12: pp. 417-427 CrossRef
- Kanis, JA, Johnell, O, Oden, A (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16: pp. 6-14 CrossRef
- Kanis, JA, Borgstrom, F, Zethraeus, Z (2005) Intervention thresholds for osteoporosis in men and women. Bone 36: pp. 22-32 CrossRef
- Duan, Y, Turner, CH, Kim, BT, Seeman, E (2001) Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss. J Bone Miner Res 16: pp. 2267-2274 CrossRef
- Duan, Y, Beck, TJ, Wang, X-F, Seeman, E (2003) Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res 18: pp. 1766-1774 CrossRef
- Wang, XF, Duan, Y, Beck, T, Seeman, ER (2005) Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone 36: pp. 978-986 CrossRef
- Seeman, E (2003) Periosteal bone formation - a neglected determinant of bone strength. New Eng J Med 349: pp. 320-323 CrossRef
- Ahlborg, HG, Johnell, O, Turner, CH, Rannevik, G, Karlsson, MK (2003) Bone loss and bone size after the menopause. N Engl J Med 349: pp. 327-334 CrossRef
- Ruff, CB, Trinkaus, E, Walker, A, Larsen, CS (1993) Postcranial robusticity in Homo. 1: temporal trends and mechanical interpretation. Am J Phys Anthropol 91: pp. 21-53 CrossRef
- Balena, R, Shih, M-S, Parfitt, (1992) Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res 7: pp. 1475-1482 CrossRef
- Riggs, BL, Melton, LJ, Robb, RA, Camp, JJ, Atkinson, EJ, Peterson, JM, Rouleau, PA, McCollough, CH, Bouxsein, ML, Khosla, S (2004) A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 19: pp. 1945-1954 CrossRef
- Khosla, S, Riggs, BL, Atkinson, EJ, Oberg, AL, McDaniel, LJ, Holets, M, Peterson, JM, Melton, LJ (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 21: pp. 124-131 CrossRef
- Aaron, JE, Makins, NB, Sagreiy, K (1987) The microanatomy of trabecular bone loss in normal aging men and women. Clin Orth RR 215: pp. 260-271
- Araujo, AB, O’Donnell, AB, Brambilla, DJ, Simpson, WB, Longcope, C, Matsumoto, AM, McKinlay, JB (2004) Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 89: pp. 5920-5926 CrossRef
- Bouillon, R, Bex, M, Vanderschueren, D, Boonen, S (2004) Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89: pp. 6025-6029 CrossRef
- Khosla, S, Melton, LJ, Riggs, BL (2002) Estrogen and the male skeleton. J Clin Endocrinol Metab 87: pp. 1443-1450 CrossRef
- Khosla, S, Melton, LJ, Atkinson, EJ, O’Fallon, WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86: pp. 3555-3561 CrossRef
- Khosla, S, Riggs, BL, Robb, RA, Camp, JJ, Achenbach, SJ, Oberg, AL, Rouleau, PA, Melton, LJ (2005) Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in men. J Clin Endocrinol Metab 90: pp. 5096-5103 CrossRef
- Orwoll, ES (2003) Toward an expanded understanding of the role of the periosteum in skeletal helath. J Bone Miner Res 18: pp. 949-954 CrossRef
- Sims, NA, Dupont, S, Krust, A, Clement-LaCroix, P, Minet, D, Resche-Rigon, M, Gaillard Kelly, M, Baron, R (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors beta in bone remodeling in females but not in males. Bone 30: pp. 18-25 CrossRef
- Sims, NA, Clement-Lacroix, P, Minet, D, Fraslon-Vanhulle, C, Gaillard-Kelly, M, Resche-Rigon, M, Baron, R (2003) A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest 111: pp. 1319-1327 CrossRef
- Szulc, P, Garnero, P, Marchand, F, Duboeuf, F, Delmas, PD (2005) Biochemical markers of bone formation reflect endosteal bone loss in elderly men-MINOS study. Bone 36: pp. 13-21 CrossRef
- Meier, C, Nguyen, TV, Center, JR, Seibel, MJ, Eisman, JA (2005) Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 20: pp. 579-587 CrossRef
- Orwoll, E, Ettinger, M, Weiss, S, Miller, P, Kendler, D, Graham, J, Adami, S, Weber, K, Lorenc, R, Pietschmann, P, Vandormael, K, Lombardi, A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: pp. 604-610 CrossRef
- Sato, Y, Iwamoto, J, Kanoko, T, Satoh, K (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165: pp. 1743-1748 CrossRef
- Ringe, JD, Faber, H, Farahmand, P, Dorst, A (2005) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 7: pp. 1-5
- Kurland, ES, Cosman, F, McMahon, DJ, Rosen, CJ, Lindsay, R, Bilezikian, JP (2000) Therapy of idiopathic osteoporosis in men with parathyroid hormone: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: pp. 3069-3076 CrossRef
- Orwoll, ES, Scheele, WH, Paul, S, Adami, S, Syversen, U, Diez-Perez, A, Kaufman, J-M, Clancy, AD, Gaich, GA (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Min Res 18: pp. 9-17 CrossRef
- Kaufman, J-M, Orwoll, E, Goemaere, S, Martin, J, Hossain, A, Dalsky, GP, Lindsay, R, Mitlak, BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16: pp. 510-516 CrossRef
- Finkelstein, JS, Hayes, A, Hunzelman, JL, Wyland, JJ, Lee, H, Neer, RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: pp. 1216-1226 CrossRef
- Kurland, ES, Heller, SL, Diamond, B, McMahon, DJ, Cosman, F, Bilezikian, JP (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporos Int 15: pp. 992-997 CrossRef
- Amory, JK, Watts, NB, Easley, KA, Sutton, PR, Anawalt, BD, Matsumoto, AM, Bremner, WJ, Tenover, JL (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89: pp. 503-510 CrossRef
- Snyder, PJ, Peachey, H, Hannoush, P, Berlin, JA, Loh, L, Holmes, JH, Dlewati, A, Staley, J, JSantanna, J, Kapoor, SC, Attie, MF, Haddad, JG (1999) Strom BL Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84: pp. 1966-1972 CrossRef
- Title
- Bone fragility in men - where are we?
- Journal
-
Osteoporosis International
Volume 17, Issue 11 , pp 1577-1583
- Cover Date
- 2006-11-01
- DOI
- 10.1007/s00198-006-0160-8
- Print ISSN
- 0937-941X
- Online ISSN
- 1433-2965
- Publisher
- Springer-Verlag
- Additional Links
- Topics
- Industry Sectors
- Authors
-
- E. Seeman (1)
- G. Bianchi (2)
- S. Khosla (3)
- J. A. Kanis (4)
- E. Orwoll (5)
- Author Affiliations
-
- 1. Austin Health, Centaur Building, Repatriation Campus, Heidelberg, 3082, Melbourne, Australia
- 2. Via Gibilrossa 10, Genova, 16148, Italy
- 3. Department of Endocrinology, Mayo Clinic, 200 1st Street, SW, Rochester, MN, 55905, USA
- 4. Centre for Metabolic Bone Disease, University of Sheffield Medical School, Beech Road Sheffield, UK
- 5. Professor of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park (CR113), Portland, OR, USA